Abstract:Background The associations between lipocalin-2 (LCN2) with mild cognitive impairment (MCI) and dementia have gained growing interest. However, population-based studies have yielded inconsistent findings. Therefore, we conducted this essential systematic review and meta-analysis to analyze and summarize the existing population-based evidence. Methods PubMed, EMBASE, and Web of Science were systematically searched until Mar 18, 2022. Meta-analysis was performed to generate the standard mean difference (SMD) of peripheral blood and cerebrospinal fluid (CSF) LCN2. A qualitative review was performed to summarize the evidence from postmortem brain tissue studies. Results In peripheral blood, the overall pooled results showed no significant difference in LCN2 across Alzheimer's disease (AD), MCI and control groups. Further subgroup analysis revealed higher serum LCN2 levels in AD compared to controls (SMD =1.28 [0.44;2.13], p = 0.003), while the difference remained insignificant in plasma (SMD =0.04 [-0.82;0.90], p = 0.931). Besides, peripheral blood LCN2 were higher in AD when age difference between AD and controls ≥4 years (SMD =1.21 [0.37;2.06], p = 0.005). In CSF, no differences were found in LCN2 across groups of AD, MCI and controls. However, CSF LCN2 was higher in vascular dementia (VaD) compared to controls (SMD =1.02 [0.17;1.87], p = 0.018), as well as compared to AD (SMD =1.19 [0.58;1.80], p < 0.001). Qualitative analysis supported that LCN2 was increased in the brain tissue of AD-related areas, especially in astrocytes and microglia; while LCN2 increased in infarct-related brain areas and over-expressed in astrocytes and macrophages in mixed dementia (MD). Conclusion The difference in peripheral blood LCN2 between AD and controls may be affected by the type of biofluid and age. No differences were found in CSF LCN2 across AD, MCI and controls groups. In contrast, CSF LCN2 was elevated in VaD patients. Moreover, LCN2 was increased in AD-related brain areas and cells in AD, while in infarcts-related brain areas and cells in MD.

Research Progress on Lipocalin-2 in Diabetic Encephalopathy

Lipocalin-2 in Diabetic Complications of the Nervous System: Physiology, Pathology, and Beyond

Lipocalin-2 as a therapeutic target for diabetes neurological complications

Review of lipocalin-2-mediated effects in diabetic retinopathy

Lipocalin-2 and Cerebral Stroke

The Association of Elevated Serum Lipocalin 2 Levels with Diabetic Peripheral Neuropathy in Type 2 Diabetes

The role of lipocalin 2 in brain injury and recovery after ischemic and hemorrhagic stroke

Emerging insights into Lipocalin-2: Unraveling its role in Parkinson's Disease

Progress in the Pathogenesis of Diabetic Encephalopathy: The Key Role of Neuroinflammation

Role of lipocalin 2 in stroke

Association between Lipocalin-2 and Mild cognitive impairment or Dementia: A systematic review and meta-analysis of population-based evidence

Effects of lipocalin 2 in obesity and its related diseases

Lipin2 ameliorates diabetic encephalopathy via suppressing JNK/ERK-mediated NLRP3 inflammasome overactivation

Lipid-related Protein NECTIN2 is an Important Marker in the Progression of Carotid Atherosclerosis: an Intersection of Clinical and Basic Studies

Pathogenic Mechanisms and Drug Research Situation in Diabetic Encephalopathy

Effects of lipocalin-2 on brain endothelial adhesion and permeability

Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy

C-peptide and diabetic encephalopathy

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia

CNDP2: An Enzyme Linking Metabolism and Cardiovascular Diseases?

Lipin1 Is Involved in the Pathogenesis of Diabetic Encephalopathy through the PKD/Limk/Cofilin Signaling Pathway